383 results about "Vascular smooth muscle" patented technology

A novel cell seeded hollow fiber bioreactor is described as a potential bioartificial kidney. Endothelial cells along with pericyte, vascular smooth muscle, and/or mesangial cells or any mesenchymally derived support cells are seeded along a hollow fiber in a perfused bioreactor to reproduce the ultrafiltration function and transport function of the kidney. Maintenance of tissue specific function and ultrastructure suggest that this bioreactor provides an economical device for treating renal failure.

Nucleic acid transfection of vascular smooth muscle cells is enhanced by the application of vibrational energy to the cells. By applying vibrational energy at frequency in the range from 1 kHz to 10 MHz and at an intensity in the range from 0.01 W/cm2 to 100 W/cm2, significant enhancement of the uptake of nucleic acids into vascular smooth muscle cells can be achieved.

The present invention provides a P2Y₁₂ receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y₁₂ receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y₁₂ receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y₁₂ receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.

The present invention provides methods, compositions, and kits for the treatment of neurocutaneous syndromes, such as neurofibromatosis type I; disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders; or for the elongation of bone. In some embodiments, the present invention provides polypeptides having an alkaline phosphatase peptide fused to an Fc domain of an immunoglobulin or a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a neurocutaneous syndrome, a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating neurocutaneous syndromes, disorders associated with overactivation of FGFR3, bone or cartilage disorders, or vascular smooth muscle disorders, or for elongating bone.

The invention provides a method for manufacturing artificial blood vessels with double-layered structures and application of the artificial blood vessels, and discloses a method for manufacturing artificial blood vessels with double-layered structures and a method for applying the artificial blood vessels. The method for manufacturing the artificial blood vessels with the double-layered structures includes a first step, manufacturing inner oriented micron fiber layers of the artificial blood vessels with the double-layered structures; a second step, manufacturing outer random nano-fiber layers of the artificial blood vessels with the double-layered structures. The method for applying the artificial blood vessels includes transplanting the double-layered artificial blood vessels in situ so as to replace lesion blood vessels. The methods have the advantages that vascular smooth muscle cells can be induced in vivo by oriented micron fibers of the inner layers of the artificial blood vessels to be regenerated just like oriented structures of natural blood vessels, sufficient suture strength and mechanical properties of the blood vessels can be guaranteed by the outer random nano-fiber layers, and accordingly the artificial blood vessels can be used for repairing and replacing the lesion natural blood vessels; the double-layered artificial blood vessels have excellent application prospects in the field of medical clinical vascular transplantation.

Disclosed are a pharmaceutical composition for inhibiting vascular smooth muscle cell proliferation comprising dimethyl fumarate as an effective ingredient, use of dimethyl fumarate for inhibiting vascular smooth muscle cell proliferation, and a method of inhibiting vascular smooth muscle cell proliferation employing the same. Through the present invention, it was found that dimethyl fumarate could inhibit vascular smooth muscle cell proliferation by increasing the activity of AMPK. Accordingly, dimethyl fumarate can be usefully used as an effective ingredient of a medicine for inhibiting vascular smooth muscle cell proliferation.

Nucleic acid transfection of vascular smooth muscle cells is enhanced by the application of vibrational energy to the cells. By applying vibrational energy at frequency in the range from 1 kHz to 10 MHz and at an intensity in the range from 0.01 W/cm2 to 100 W/cm2, significant enhancement of the uptake of nucleic acids into vascular smooth muscle cells can be achieved.

Methods and compositions are disclosed for inhibiting proliferation of human colon adenocarcinoma cells, reducing pro-inflammatory molecules, adhesion molecules, and vascular smooth muscle cell proliferation, and for increasing NO production. The present invention describes the use of phenolic compositions, purified from oats or synthetically produced, to decrease the effective amount of pro-inflammatory molecules and/or cell adhesion molecules. Alternatively, an alcoholic extract or concentrate from oats can be used. The methods of the present invention can be used as a treatment or prophylaxis of a wide variety of disorders associated with inflammatory states and/or with a lack of or need for nitric oxide (NO), such as inflammatory conditions, pain, free radical associated disorders, cardiovascular diseases, autoimmune disorders, pathological platelet aggregation, pathological vasoconstriction, vascular effects of diabetes, stroke, atherosclerosis, hypertension, abnormal vasospasm, and restenosis after angioplasty.

The present invention provides methods, compositions, and kits for the treatment of disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders, or for the elongation of bone. In some embodiments, the present invention provides polypeptides having a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating disorders associated with overactivation of FGFR3, bone or cartilage disorders, or vascular smooth muscle disorders, or for elongating bone.

Methods are provided for inhibiting or treating stenosis or restenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective amount of a therapeutic agent via a catheter. Also provided is a catheter adapted for administering a therapeutically effective amount of a therapeutic agent to a mammalian host for inhibiting or treating stenosis or restenosis.

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

The invention discloses a biological small-diameter artificial blood vessel and preparation method thereof. The method comprises a step of crosslinking the natural extracellular matrix of vessels by using procyanidins. The small-diameter artificial blood vessel of the invention has the characteristics of improved mechanical strength and stability, non-toxicity, enzymatic degradation resistance in vivo, anti-calcification, platelet adhesion resistance, low immunogenicity, and very little protein release from cross-linking agent and the small-diameter vessel. These crosslinking characteristics are beneficial for the immigration, prolongation, and long-term anti-calcification of the small-diameter vascular smooth muscle cells and vascular endothelial cells of a human body itself after the small-diameter artificial blood vessel is implanted in the human body.

The invention relates to a biologic polypeptide medicine blood vessel support and a preparation method thereof. The biologic polypeptide medicine blood vessel support comprises a support body and active medicines. The support body which is medical material with pores and good biocompatibility is made from stainless steel, cobalt-base alloy, titanium alloy, nickel-titanium alloy or polylactic acid biopolymer; the active medicines comprise a biologic polypeptide medicine and a smooth muscle cell proliferation inhibition medicine. The support is characterized in that: the support body with the pores has the biologic polypeptide medicine fixed on the internal surface of the body and the smooth muscle cell proliferation inhibition medicine coated on the external surface of the body. The preparation me(3) carrying out the after-treatment of the surface of the support body; (4) preparing the medicines; (5) coating the external surface; (6) fixing the medicine onto the internal surface; (7) carrying out the process step of low temperature drying. The support can selectively absorb endothelium progenitor cells which quickly differentiate into endothelium cells to promote the restoration of the endothelium after the support is built in; the support can also effectively inhibit the proliferation and migration of vascular smooth muscle cells, persistently and effectively reduce the formation of a new inner membrane, effectively prevent restenosis inside the support, and avoid the risk of potentially fatal late thrombosis.

The present invention provides compounds of Formula (I):

or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

The invention relates to a method for the in vitro detection of vasculitis or the risk of developing vasculitis, including determining the presence and/or the amount of anti-endothelial cell antibodies (AECA) or anti-vascular smooth muscle cell (VSMC) antibodies in a biological sample from a patient.

The invention belongs to the field of high polymer materials and biomedical engineering, and particularly relates to a bionic vascular stent and a preparation method thereof. The bionic vascular stent comprises a bare stent for supporting, a drug-loaded degradable polymer coating, and a polymer coating containing a phosphorylcholine group and an Arg-Clu-Asp-Val (REDV) polypeptide (or molecules, capable of specifically combining endothelial cells and endothelial progenitor cells, of a CD34 antibody, a CD133 antibody and the like). The stent is applied to a vascular disease position; the degradable polymer coating on the outer wall of the stent gradually releases the loaded drug and inhibits vascular smooth muscle proliferation to prevent vascular restenosis after the stent is implanted; the polarity of the stent platform can be changed by the phosphorylcholine group in the coating at the inner side of the stent; the biocompatibility of the stent surface is improved; adhesive growth of the endothelial cells and the endothelial progenitor cells can be promoted by specific recognition sites of the endothelial cells/endothelial progenitor cells of REDV and the like; and the endothelialization progress of the stent surface is accelerated.